Familial Mediterranean Fever (FMF )
Conditions
Brief summary
retrospective observe the efficacy and safety of different drugs used in familial Mediterranean fever (FMF) cases in real-world
Interventions
DRUGreal word drugs
real word drugs
Sponsors
Tongji Hospital
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Pfizer
Johns Hopkins University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
\- Clinical diagnosis of Familial Mediterranean fever (FMF) patients (Tel Hashomer criteria)
Exclusion criteria
* Have a history of mental illness, or alcohol and drug dependence； * Pregnant, with severe infection, severe cardiac insufficiency, severe liver or kidney dysfunction； * Complicated with tumors, organ transplants, etc. which have significant impact on the immune system or require the use of immunosuppressants.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical responses graded as Patient Global Assessment (PGA ) decrease | From baseline,4, 8, 12, 24 and week 52 | The treatment outcome was graded as PGA decrease:in-response, partial response, good response, or clinical remission corresponding to symptomatic improvement \<30%, 30% to 50%, 50% to 70%, or \>70%, respectively. PGA is a subjective measure where patients rate their overall disease activity or health status on a scale like a visual analog scale (VAS). |
Countries
China
Contacts
CONTACTYikai Yu
Outcome results
None listed